Novo Nordisk A/S, the Danish producer of diabetes products, reported a 3.4% advance in revenue to DKK 20.5 billion (€2.75 billion) in the third quarter and a 13.2% rise in net profit to DKK 6.4 billion. ---Subscribe to MedNous to access this article--- Company News
